Guizhou Sanli Pharmaceutical Co.,Ltd

¥10.84As of Sun 8 Nov 2026, 12:00 UTC
SSE:603439Healthcare
Country China
PE (Fwd) •••
TSR 7Y CAGR (1.46%)
Div yield 0.55%
ROE 3.38%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 1.06
PE TTM 85.22
TSR TTM (9.92%)
Mkt cap ¥4.332B
ROIC 7.47%
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥11
4.36%
(62.05%)
Hold 5|4|6|8|5
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.20
0.22
0.23
0.24
27.08%
30.72%
32.64%
31.06%
Revenue¥M
248.3
259.0
259.9
273.8
0.51%
4.46%
6.92%
8.14%
Peers (US$649.4M)
Cap (US$)
PE
652.7M
139.3x
Capital
TTM
5Y
10Y
Leveragex
1.296
1.457
1.048
EBIT/Intx
9.207
0.145
0.161
Own earn%
(20.29)
8.54
5.72
Sh yield%
40.66
30.47
23.75
Owners
Insiders/Inst%
6.32
33.17
Short interest%
2.21
SBC / revenue%
2.31
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
6
Op margin range%
6–13
$1 testx
—
Incr. ROIC%
4